AU2016267392B2 - Validating biomarker measurement - Google Patents

Validating biomarker measurement Download PDF

Info

Publication number
AU2016267392B2
AU2016267392B2 AU2016267392A AU2016267392A AU2016267392B2 AU 2016267392 B2 AU2016267392 B2 AU 2016267392B2 AU 2016267392 A AU2016267392 A AU 2016267392A AU 2016267392 A AU2016267392 A AU 2016267392A AU 2016267392 B2 AU2016267392 B2 AU 2016267392B2
Authority
AU
Australia
Prior art keywords
biomarker
values
value
biomarker values
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016267392A
Other languages
English (en)
Other versions
AU2016267392A1 (en
Inventor
Leo Charles Mchugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunexpress Pty Ltd
Original Assignee
Immunexpress Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901982A external-priority patent/AU2015901982A0/en
Application filed by Immunexpress Pty Ltd filed Critical Immunexpress Pty Ltd
Publication of AU2016267392A1 publication Critical patent/AU2016267392A1/en
Application granted granted Critical
Publication of AU2016267392B2 publication Critical patent/AU2016267392B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Bioethics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016267392A 2015-05-28 2016-05-20 Validating biomarker measurement Active AU2016267392B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901982 2015-05-28
AU2015901982A AU2015901982A0 (en) 2015-05-28 Validating biomarker measurement
PCT/AU2016/050388 WO2016187655A1 (en) 2015-05-28 2016-05-20 Validating biomarker measurement

Publications (2)

Publication Number Publication Date
AU2016267392A1 AU2016267392A1 (en) 2017-12-07
AU2016267392B2 true AU2016267392B2 (en) 2021-12-09

Family

ID=57392259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016267392A Active AU2016267392B2 (en) 2015-05-28 2016-05-20 Validating biomarker measurement

Country Status (9)

Country Link
US (2) US10719579B2 (https=)
EP (1) EP3304093B1 (https=)
JP (1) JP2018525703A (https=)
CN (1) CN108323184A (https=)
AU (1) AU2016267392B2 (https=)
CA (1) CA2986787A1 (https=)
DK (1) DK3304093T3 (https=)
HK (1) HK1249182A1 (https=)
WO (1) WO2016187655A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
EP3879535B1 (en) * 2017-06-13 2024-12-11 BostonGene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
US11430543B2 (en) * 2017-08-04 2022-08-30 Billiontoone, Inc. Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
KR102633621B1 (ko) 2017-09-01 2024-02-05 벤 바이오사이언시스 코포레이션 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
CN109055535A (zh) * 2018-09-14 2018-12-21 北京泱深生物信息技术有限公司 血液中的分子作为诊断脓毒症的标志物
CN109374904A (zh) * 2018-10-29 2019-02-22 浙江医院 一种蛋白质类脓毒症标志物及其在严重脓毒症早期预警的应用及其筛选方法
IL292346B2 (en) 2019-11-05 2025-02-01 Apeel Tech Inc Predicting contamination in plant products
US11049590B1 (en) 2020-02-12 2021-06-29 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
WO2021202620A1 (en) * 2020-03-31 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Metabolomics approach combined with machine learning to recognize a medical condition
CN113488107B (zh) * 2021-07-07 2022-07-19 广州华银康医疗集团股份有限公司 筛选免疫组库测序生物标志物的方法、设备和存储介质
EP4195212A1 (en) * 2021-12-08 2023-06-14 A3P Biomedical AB (publ) Certainty-based medical conclusion model adaptation
CN114628024A (zh) * 2022-02-24 2022-06-14 重庆市急救医疗中心(重庆市第四人民医院、重庆市急救医学研究所) 一种生物标志物组在制备用于辅助筛查脓毒症的产品中的用途和辅助筛查方法及其系统
WO2025094604A1 (ja) * 2023-10-31 2025-05-08 アークレイ株式会社 検知方法、検知装置、検知システム、検知プログラム、及び記録媒体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180365A1 (en) * 2002-12-13 2004-09-16 Affymetrix, Inc. Methods and computer software products for gene expression data quality analysis
US20140120545A1 (en) * 2011-04-18 2014-05-01 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148339A1 (en) 2001-05-07 2003-08-07 Hrissi Samartzidou Artificial genes for use as controls in gene expression analysis systems
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CA2577741A1 (en) 2004-08-18 2006-03-02 Abbott Molecular, Inc. Determining data quality and/or segmental aneusomy using a computer system
CA2605143A1 (en) * 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20070255113A1 (en) * 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
US20080213768A1 (en) * 2006-08-17 2008-09-04 Zhauhui Cai Identification and use of biomarkers for non-invasive and early detection of liver injury
DE102007010252B4 (de) 2007-03-02 2013-07-04 Sirs-Lab Gmbh Kontrollgene zur Normalisierung von Genexpressionsanalysedaten
CA2604317C (en) * 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
JP4666237B2 (ja) 2008-07-09 2011-04-06 ソニー株式会社 遺伝子検定方法、遺伝子検定プログラム及び遺伝子検定装置
US9217747B2 (en) * 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20120035860A1 (en) 2010-04-29 2012-02-09 Akmaev Viatcheslav R GC Wave Correction for Array-Based Comparative Genomic Hybridization
US20140037649A1 (en) * 2010-11-26 2014-02-06 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
CA2877975C (en) * 2012-04-13 2021-09-21 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180365A1 (en) * 2002-12-13 2004-09-16 Affymetrix, Inc. Methods and computer software products for gene expression data quality analysis
US20140120545A1 (en) * 2011-04-18 2014-05-01 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERKER, J.D. et al., "Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory", Journal of Molecular Diagnostics, (2010), vol. 12, pages 58 - 64 *

Also Published As

Publication number Publication date
CA2986787A1 (en) 2016-12-01
JP2018525703A (ja) 2018-09-06
HK1249182A1 (zh) 2018-10-26
US20180107783A1 (en) 2018-04-19
US10719579B2 (en) 2020-07-21
US20160350477A1 (en) 2016-12-01
AU2016267392A1 (en) 2017-12-07
WO2016187655A1 (en) 2016-12-01
EP3304093A4 (en) 2019-02-06
CN108323184A (zh) 2018-07-24
EP3304093A1 (en) 2018-04-11
DK3304093T3 (da) 2024-02-12
EP3304093B1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
AU2016267392B2 (en) Validating biomarker measurement
US20210040562A1 (en) Methods for evaluating lung cancer status
US11776661B2 (en) Determination of MAPK-AP-1 pathway activity using unique combination of target genes
US11649488B2 (en) Determination of JAK-STAT1/2 pathway activity using unique combination of target genes
US12125561B2 (en) Determination of JAK-STAT3 pathway activity using unique combination of target genes
US9238841B2 (en) Multi-biomarker-based outcome risk stratification model for pediatric septic shock
US20190018930A1 (en) Method for building a database
US12297505B2 (en) Algorithms for disease diagnostics
Verboom et al. Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients
Risueño et al. A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples
Xie et al. 3 CpG methylation biomarkers for the diagnosis of polycystic ovary syndrome (PCOS) in blood samples
US20240363197A1 (en) Methods for characterizing infections and methods for developing tests for the same
Krumm et al. Diagnosis of ovarian carcinoma homologous recombination DNA repair deficiency from targeted gene capture oncology assays
US20240035090A1 (en) mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE
US20230071390A1 (en) Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
Berndt et al. A multivariate cell-based assay for blood-based diagnostics enhances lung cancer risk stratification
US20250305051A1 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
CN117305444A (zh) 利用癌症中剪接异常的短外显子辅助癌症诊断和预后
Valbuena et al. 1Scientific RepoRtS|(2019) 9: 15787| https://doi. org/10.1038/s41598-019-51948-6 www. nature. com/scientificreports The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)